FDAnews/CenterWatch Announces -- Real World Evidence and Data in Clinical Trials: A Tufts Study of 30 Pharma Companies Webinar Aug. 13, 2020

Using RWE in the next trial? Experts explain current and planned use of RWE in support of development and post-approval safety studies.

News provided by

FDAnews

Jul 30, 2020, 13:00 ET

FALLS CHURCH, Va., July 30, 2020 /PRNewswire-PRWeb/ -- Real World Evidence and Data in Clinical Trials:
A Tufts Study of 30 Pharma Companies
A CenterWatch/FDAnews Webinar
Thursday, Aug. 13, 2020 • 1:30-3:00 p.m. EDT
https://www.centerwatch.com/realworldevidence

Considering using real world evidence (RWE) in the next clinical trial? The Tufts Center for the Study of Drug Development (CSDD) study can provide valuable insights.

The CSDD investigated 30 biopharmaceutical companies to determine how the industry is using real world data (RWD) and RWE. The study sheds light on the primary uses of RWD to generate evidence and identifies gaps and challenges in using RWE. The speakers will walk attendees through the study's important takeaways.

Mary Jo Lamberti, PhD, a Tufts University professor and associate director of sponsored research at the CSDD, along with Francis Kendall, a 30-year pharmaceutical industry veteran and senior director at Cytel where he is a key member on the company's real world analytics team, will discuss cases of what is being done with RWE and RWD.

Based on their knowledge, and using several recent case studies, Dr. Lamberti and Mr. Kendall will share valuable information on:

  • Types of technology used to access or collect real world data and evidence and partnerships that support usage
  • Significant challenges to using RWD
  • Strategies and practices that impact return on investment or performance
  • Key drivers for change and the adoption of RWE
  • The potential of RWE and how it may be used across the clinical development pipeline
  • A view on what will happen next in the RWE domain
  • A look into regulators position regarding COVID-19 studies

Understand the critical factors needed to consider in using RWE, and gain insight into the current and planned uses of RWE to support development and post-approval safety studies.

Interested in registering multiple sites?
Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
to learn about our special multisite discount.

Webinar Details:
Real World Evidence and Data in Clinical Trials:
A Tufts Study of 30 Pharma Companies
A CenterWatch/FDAnews Webinar
Thursday, Aug. 13, 2020 • 1:30-3:00 p.m. EDT
https://www.centerwatch.com/realworldevidence

Tuition:
$287 per site

Easy Ways to Register:
Online: https://www.centerwatch.com/realworldevidence
By phone: 888.838.5578 or 703.538.7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations

About CenterWatch:
Founded in 1994, CenterWatch is a trusted source and global destination for clinical trials information for both professionals and patients. CenterWatch provides proprietary data and information analysis on clinical trials through a variety of newsletters, books, databases, and information services used by pharmaceutical and biotechnology companies, CROs, SMOs, and investigative sites involved in the management and conduct of clinical trials. As a pioneer in publishing clinical trials information, CenterWatch was the first Internet site to publish detailed information about active clinical trials that could be accessed by patients and their advocates.

SOURCE FDAnews